Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders |
Mechanism AR degraders(Androgen Receptor degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC47H53ClN6O7 |
InChIKeyGJKHWPITFRGJJH-KRRCZHMUSA-N |
CAS Registry2756586-39-5 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rosacea | Preclinical | China | 05 Mar 2026 | |
| Prostatic Cancer | Preclinical | China | 01 Apr 2021 | |
| Prostatic Cancer | Preclinical | China | 01 Apr 2021 |





